Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

PHASE1RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor
Interventions
DRUG

MRTX1719

"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"

Trial Locations (24)

10021

RECRUITING

David H Koch, Memorial Sloan Kettering Cancer Center, New York

11776

RECRUITING

New york cancer and blood specialists - Oncology, Port Jefferson Station

RECRUITING

New york cancer and blood specialists - Oncology, Port Jefferson Station

22031

RECRUITING

Virginia Cancer Specialists, PC, Fairfax

27599

RECRUITING

University of North Carolina, Chapel Hill

32224

RECRUITING

Mayo Clinic, Jacksonville

32827

RECRUITING

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

49444

RECRUITING

Cancer and Hematology Centers of Western Michigan, Norton Shores

53226

RECRUITING

Medical College of Wisconsin - Froedtert Hospital, Milwaukee

55905

RECRUITING

Mayo Clinic, Rochester

60637

WITHDRAWN

Local Institution - 124, Chicago

75235

RECRUITING

Ut Southwestern, Dallas

76104

RECRUITING

Texas Oncology - DFW, Fort Worth

77030

COMPLETED

Local Institution - 108, Houston

RECRUITING

MDACC, Houston

78229

RECRUITING

South Texas Accelerated Research Therapeutics, San Antonio

78503

RECRUITING

Texas Oncology, P.A. - Oncology, Tyler

80124

RECRUITING

Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree

98109

WITHDRAWN

Local Institution - 134, Seattle

85054-4502

RECRUITING

Mayo Clinic, Phoenix

80218-1238

RECRUITING

Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver

02251

RECRUITING

Dana-Farber Cancer Institute, Brookline

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

37232-5505

RECRUITING

Vanderbilt - Ingram Cancer Center, Nashville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05245500 - Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Biotech Hunter | Biotech Hunter